The present invention relates generally to site markers for breast biopsy procedures. More specifically, the present invention relates to site markers that are visible under multiple modalities.
In the diagnosis and treatment of breast cancer, it is often necessary to perform a biopsy to remove tissue samples from a suspicious mass. The suspicious mass is typically discovered during a preliminary examination involving visual examination, palpation, X-ray, magnetic resonance imaging (MRI), ultrasound imaging or other detection means.
When a suspicious mass is detected, a sample is taken by biopsy, and then tested to determine whether the mass is malignant or benign. This biopsy procedure can be performed by an open surgical technique, or through the use of a specialized biopsy instrument. To minimize surgical intrusion, a small specialized instrument such as a biopsy needle is inserted in the breast while the position of the needle is monitored using fluoroscopy, ultrasonic imaging, X-rays, MRI or other suitable imaging techniques.
In a relatively new procedure, referred to as stereotactic needle biopsy, the patient lies on a special biopsy table with her breast compressed between the plates of a mammography apparatus and two separate X-rays are taken from two different points of reference. A computer then calculates the exact position of the mass or lesion within the breast. The coordinates of the lesion are then programmed into a mechanical stereotactic apparatus which advances the biopsy needle into the lesion with precision. At least five biopsy samples are usually taken from locations around the lesion and one from the center of the lesion.
Regardless of the method or instrument used to perform the biopsy, subsequent examination of the surgical site may be necessary, either in a follow up examination or for treatment of a cancerous lesion. Treatment often includes a mastectomy, lumpectomy, radiation therapy, or chemotherapy procedure that requires the surgeon or radiologist to direct surgical or radiation treatment to the precise location of the lesion. Because this treatment might extend over days or weeks after the biopsy procedure, and the original features of the tissue may have been removed or altered by the biopsy, it is desirable to insert a site marker into the surgical cavity to serve as a landmark for future identification of the location of the lesion.
Known biopsy site markers have been found to have disadvantages in that the site markers are not visible under all available modalities. Moreover, because of this problem, when cancer is found at a biopsy site that has been previously marked with a site marker, due to the poor visibility of the biopsy site marker under ultrasound or other visualization modalities, the patient must undergo an additional procedure that places an additional device the biopsy site to enable the surgeon to find the biopsy site in subsequent procedures. One known technique has been to place a breast leasion localization wire at the biopsy site. The localization wire is typically placed at the biopsy site via mammography and/or ultrasound.
Accordingly, there is a need for site markers made from biocompatible materials that are visible under various modes of imaging to reduce the number of procedures that patients must undergo in detection and treatment of cancer.
A site marker is provided that includes a generally hollow body defining a cavity. At least one marker element is captured within the cavity but is able to move within the cavity. The capturing prevents migration of the marker within a body. The site marker is formed into a predeployment configuration whereby the site marker is compressed into a predetermined size and shape to as to be readily positionable within a deployment device. The site marker expands from the predeployment position to a post deployment configuration upon insertion into the body.
Alternative embodiments may include a site marker having a solid beam defined by a relatively planar top and bottom surfaces. The beam resonates when subjected to a predetermined ultrasound frequency, thereby making the solid beam visible under multiple imaging modalities. In another embodiment, a site marker for implantation in a biopsy cavity is provided including a plurality of solid glass beads wherein the glass beads are fused together to form a unitary body.
In yet another embodiment, a site marker is provided including a body portion constructed of a shape memory material. The body portion is constructed into a predetermined size and shape and is selectively compressed into a pre-deployment configuration. The body portion automatically expands to a post-deployment configuration that corresponds to the predetermined size and shape of the body portion upon release from the compression of the pre-deployment configuration. In still another embodiment, a site marker is provided including a marker head and at least one appendage attached to the marker head and extending therefrom.
These and other features and advantages of the invention will be apparent from the following detailed description and the appended claims, taken in conjunction with the accompanying drawings, in which:
Referring initially to
In another aspect of the invention, the particles 28 may be sufficiently small such that, when sintered together, the resultant site marker 32 appears to form a porous metal, as shown in
In another embodiment,
In one embodiment, body portion 82 is constructed of a bioabsorbable material such as polyglycolic acid (PGA), polylactic acid (PLA), hydrogel, collegen-based material or any other suitable material. The bioabsorbable material may be woven into a flexible mesh that has openings formed therein that are sized so as to be smaller than permanent marker 88 such that permanent marker 88 cannot escape body portion 82. After installation in a biopsy cavity, over a predetermined time period such as three weeks to six months, body portion 82 is absorbed by the body, such that only permanent marker 88 remains within the body at the biopsy cavity. Because permanent marker 88 is captured within body portion 82 prior to absorption thereof by the body, permanent marker 88 is restricted from migrating from within the biopsy cavity. Indeed, movement of permanent marker 88 is limited to the internal cavity defined by body portion 82. This insures that permanent marker 88 remains within the biopsy cavity to permit follow-up imaging of the biopsy site.
In one embodiment, prior to deployment into the biopsy site by a suitable deployment mechanism, site marker 80, and more specifically, body portion 82 is formed in a first pre-deployment configuration (as shown in
In another embodiment, as shown in
In another embodiment, as shown in
Another embodiment of a site marker 90 is shown in
In an alternative embodiment, as shown in
In one embodiment, site marker 90, 90′ and flange 96 is constructed from titanium or other suitable material. In another embodiment, site marker 90, 90′ is constructed from a solid piece of material such that it has no sealed chambers or regions that contain gas or air.
In yet another site marker design, the site marker contains a plurality of solid glass beads that are fused together similar to the sintered site marker 24 described above in connection with
Site marker 100 expands from a first pre-deployment configuration (shown in
In one embodiment, the material may from which site marker 100 is constructed is a shape memory material that will spring into the second post deployment configuration upon release from a deployment device into a biopsy cavity. In accordance with this embodiment, the site marker is designed to have a predetermined shape and then compressed into the first pre-deployment configuration. The site marker is then retained in the first pre-deployment configuration and may be loaded into a deployment device. It should be noted that the site marker may be stored in the deployment device in the first pre-deployment configuration for an extended period of time.
Once released from the deployment device and into the biopsy cavity, the site marker automatically springs into the second post-deployment configuration having a predetermined size and shape such that the site marker is easily visible under various imaging modalities.
In another embodiment, site marker 100 is constructed of a temperature dependent material. In accordance with this embodiment, the site marker does not expand from the first pre-deployment configuration into the second post-deployment configuration until heat is applied to the site marker 100. Deploying the site marker 100 into a biopsy cavity provides a sufficient level of heat generated from the body to enable site marker 100 to automatically expand into the second post-deployment configuration after deployment.
In another embodiment, shown in
In one embodiment, the appendages 106 attached to the marker head 104 are semi-rigid and constructed of a heat activated material that causes the appendages 106 to curl outwardly once received in the body (See
Alternatively, the appendages 106 may be constructed of a memory-shape material whereby the appendages 106 are preformed with curled, outwardly extending ends 108. The appendages 106 are then compressed into a pre-deployment configuration, such as that shown in
In another embodiment, as shown in
In another embodiment of the present invention, shown in
In one embodiment, the material may from which site marker 120 is constructed is a shape memory material that will spring into the second post deployment configuration upon release from a deployment device into a biopsy cavity. In accordance with this embodiment, the site marker 120 is designed to have a predetermined shape and then compressed into the first pre-deployment configuration. The site marker 120 is then retained in the first pre-deployment configuration and may be loaded into a deployment device. It should be noted that the site marker 120 may be stored in the deployment device in the first pre-deployment configuration for an extended period of time.
Once released from the deployment device and into the biopsy cavity, the site marker 120 automatically springs into the second post-deployment configuration having a predetermined size and shape such that the site marker 120 is easily visible under various imaging modalities.
In another embodiment, site marker 120 is constructed of a temperature dependent material. In accordance with this embodiment, the site marker 120 does not expand from the first pre-deployment configuration into the second post-deployment configuration until heat is applied to the site marker 120. However, deploying the site marker 120 into a biopsy cavity provides a sufficient level of heat generated from the body to enable site marker 120 to automatically expand into the second post-deployment configuration after deployment.
Yet another embodiment of a site marker 122, is shown in
Contained within the tetrahedron shell is a marker 126 that is visible under one or more modalities. By having the marker 126 contained within the shell, the marker 126 is prevented from migrating. Indeed, the marker 126 may only move within the shell. In one embodiment, marker 126 is a permanent marker that will not become absorbed by the body. Alternatively, marker 126 may be a non-permanent marker that remains within the body for a predetermined length of time.
In an alternative embodiment, site marker 122′ may be formed to have a double tetrahedron shell as shown in
Both site marker 122 and 122′ may be compressed into a first pre-deployment configuration, such as that shown in
Once deployed by a suitable deployment device or released from the first, pre-deployed configuration, the pre-biased spines 124, 124′ of site markers 122 and 122′ automatically return to site markers 122 and 122′ to the deployed configurations shown in
Yet another embodiment of a site marker 128 is shown in
In yet another alternative embodiment, base spines 133 are eliminated such that the remaining spines 132 within tube 130 are biased to form capped ends when the site marker 128 is in a deployed configuration.
To deploy the embodiments described in connection with
While the present invention has been particularly shown and described with reference to the foregoing preferred embodiments, it should be understood by those skilled in the art that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention without departing from the spirit and scope of the invention as defined in the following claims. It is intended that the following claims define the scope of the invention embodiments within the scope of these claims and their equivalents be covered thereby. This description of the invention should be understood to include all novel and non-obvious combinations of elements described herein, and claims may be presented in this or a later application to any novel and non-obvious combination of these elements. The foregoing embodiment is illustrative, and no single feature or element is essential to all possible combinations that may be claimed in this or a later application.
This application is a Continuation-in-part of U.S. application Ser. No. 10/964,087, entitled SITE MARKER VISIBLE UNDER MULTIPLE MODALITIES, filed Oct. 13, 2004.
Number | Name | Date | Kind |
---|---|---|---|
4774957 | Nambu et al. | Oct 1988 | A |
4991579 | Allen | Feb 1991 | A |
5010145 | Ikada et al. | Apr 1991 | A |
5016639 | Allen | May 1991 | A |
5097839 | Allen | Mar 1992 | A |
5104539 | Anderson et al. | Apr 1992 | A |
5211164 | Allen | May 1993 | A |
5218964 | Sepponen | Jun 1993 | A |
5368030 | Zinreich et al. | Nov 1994 | A |
5397329 | Allen | Mar 1995 | A |
5427099 | Adams | Jun 1995 | A |
5469847 | Zinreich et al. | Nov 1995 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5730130 | Fitzpatrick et al. | Mar 1998 | A |
5769789 | Wang et al. | Jun 1998 | A |
5782764 | Werne | Jul 1998 | A |
5902310 | Foerster et al. | May 1999 | A |
5941890 | Voegele et al. | Aug 1999 | A |
5961455 | Daum et al. | Oct 1999 | A |
6011987 | Barnett | Jan 2000 | A |
6015844 | Harvey et al. | Jan 2000 | A |
6016439 | Acker | Jan 2000 | A |
6056700 | Burney et al. | May 2000 | A |
6173715 | Sinanan et al. | Jan 2001 | B1 |
6228055 | Foerster et al. | May 2001 | B1 |
6231834 | Unger et al. | May 2001 | B1 |
6261302 | Voegele et al. | Jul 2001 | B1 |
6270464 | Fulton, III et al. | Aug 2001 | B1 |
6280385 | Melzer et al. | Aug 2001 | B1 |
6333971 | McCrory et al. | Dec 2001 | B2 |
6347241 | Burbank et al. | Feb 2002 | B2 |
6350244 | Fisher | Feb 2002 | B1 |
6356782 | Sirimanne et al. | Mar 2002 | B1 |
6371904 | Sirimanne et al. | Apr 2002 | B1 |
6379379 | Wang | Apr 2002 | B1 |
6427081 | Burbank et al. | Jul 2002 | B1 |
6466813 | Shukla et al. | Oct 2002 | B1 |
6544185 | Montegrande | Apr 2003 | B2 |
6567687 | Front et al. | May 2003 | B2 |
6628982 | Thomas et al. | Sep 2003 | B1 |
6640127 | Kosaka et al. | Oct 2003 | B1 |
6687533 | Hirano et al. | Feb 2004 | B1 |
6699205 | Fulton, III et al. | Mar 2004 | B2 |
6725083 | Burbank et al. | Apr 2004 | B1 |
6766186 | Hoyns et al. | Jul 2004 | B1 |
7229417 | Foerster et al. | Jun 2007 | B2 |
7611462 | Vortman et al. | Nov 2009 | B2 |
7625397 | Foerster et al. | Dec 2009 | B2 |
20010049549 | Boylan et al. | Dec 2001 | A1 |
20020035324 | Sirimanne et al. | Mar 2002 | A1 |
20020082517 | Klein | Jun 2002 | A1 |
20020156372 | Skakoon et al. | Oct 2002 | A1 |
20020161298 | Burbank et al. | Oct 2002 | A1 |
20020188196 | Burbank et al. | Dec 2002 | A1 |
20020193815 | Foerster et al. | Dec 2002 | A1 |
20030004563 | Jackson et al. | Jan 2003 | A1 |
20030097059 | Sorrell et al. | May 2003 | A1 |
20030139669 | Montegrande | Jul 2003 | A1 |
20030199785 | Hibner et al. | Oct 2003 | A1 |
20040030237 | Lee et al. | Feb 2004 | A1 |
20040030262 | Fisher et al. | Feb 2004 | A1 |
20040049126 | Zarins et al. | Mar 2004 | A1 |
20040049224 | Buehlmann et al. | Mar 2004 | A1 |
20040093069 | Priewe et al. | May 2004 | A1 |
20040097981 | Selis | May 2004 | A1 |
20040105890 | Klein et al. | Jun 2004 | A1 |
20040110059 | Onishi et al. | Jun 2004 | A1 |
20040116802 | Jessop et al. | Jun 2004 | A1 |
20040116805 | Chesbrough et al. | Jun 2004 | A1 |
20040116806 | Burbank et al. | Jun 2004 | A1 |
20040138555 | Krag et al. | Jul 2004 | A1 |
20040219186 | Ayres | Nov 2004 | A1 |
20050033157 | Klein et al. | Feb 2005 | A1 |
20050063908 | Burbank et al. | Mar 2005 | A1 |
20050277871 | Selis | Dec 2005 | A1 |
20050288764 | Snow et al. | Dec 2005 | A1 |
20060079805 | Miller et al. | Apr 2006 | A1 |
20060173296 | Miller et al. | Aug 2006 | A1 |
20070093726 | Leopold et al. | Apr 2007 | A1 |
20070118176 | Opolski et al. | May 2007 | A1 |
20070167980 | Figulla et al. | Jul 2007 | A1 |
20080058715 | Houser et al. | Mar 2008 | A1 |
20080269603 | Nicoson | Oct 2008 | A1 |
Number | Date | Country |
---|---|---|
1491147 | Dec 2004 | EP |
1579878 | Sep 2005 | EP |
1 602 341 | Dec 2005 | EP |
1 925 266 | May 2008 | EP |
WO-0024332 | May 2000 | WO |
WO-0100101 | Jan 2001 | WO |
WO-0108578 | Feb 2001 | WO |
WO-0230482 | Apr 2002 | WO |
WO-2004012600 | Feb 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20060173296 A1 | Aug 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10964087 | Oct 2004 | US |
Child | 11242334 | US |